Cerebrolysin (60mg)
Cerebrolysin is a porcine brain-derived neuropeptide preparation containing low-molecular-weight peptides and free amino acids that cross the blood-brain barrier to support neuronal survival and neuroplasticity. By mimicking endogenous neurotrophic factors (NGF, BDNF), Cerebrolysin may enhance cognitive function, memory, and neuroprotection. This protocol outlines a once to twice daily subcutaneous approach.
Reviewed by the AllPeptides.eu Editorial Team·Last reviewed: 2026-06-16
Educational information. Not medical advice, and no efficacy claim is implied. Regulatory approval is not a use recommendation by AllPeptides.eu.
⚠️ For informational/educational purposes only. Not medical advice. We do not sell any products. Self-treatment carries serious risks — consult a healthcare professional. Disclaimer
How It Works
Cerebrolysin consists of enzymatically prepared low-molecular-weight neuropeptides (<10 kDa) and free amino acids derived from porcine brain tissue. These components cross the blood-brain barrier and exert multimodal neurotrophic and neuroprotective effects by mimicking endogenous growth factors (NGF, BDNF). Preclinical and clinical studies show support for neuronal survival, enhancement of synaptic plasticity, modulation of neuroinflammatory pathways, and potential promotion of functional recovery after stroke or traumatic brain injury.
Quick Start
- Reconstitution: Add 3.0 mL of bacteriostatic water → 20 mg/mL concentration.
- Typical daily range: 20–32 mg once or twice daily (gradual titration over 3–4 weeks).
- Storage: Lyophilized: ≤25 °C; after reconstitution, refrigerate at 2–8 °C; use within 7 days; do not freeze.
Typical / Gradual Titration (3 mL = 20 mg/mL)
Route: Subcutaneously | Frequency: Once or twice daily
| Week | Dose | Units (per injection) |
|---|---|---|
| Week 1 | 20 mg | 100 Units (1.00 mL) |
| Week 2 | 24 mg | 2 × 60 Units (0.60 mL) |
| Week 3 | 28 mg | 2 × 70 Units (0.70 mL) |
| Week 4+ | 32 mg | 2 × 80 Units (0.80 mL) |
Studies report administration once daily subcutaneously in Wk 1, then twice daily (AM/PM) from Wk 2 so that each injection does not exceed 1.0 mL. Morning administration is preferred due to mild stimulant properties.
Related compounds
Reconstitution Steps
- Draw up 3.0 mL of bacteriostatic water.
- Slowly inject onto the vial wall; avoid foaming.
- Gently swirl/rotate until dissolved.
- Note date/time and refrigerate at 2–8 °C; use within 7 days.
Protocol Overview
- Objective: Neuroprotection and neuronal survival via NGF/BDNF-like neurotrophic support.
- Schedule: Daily subcutaneous injections for 8–12 weeks (extendable to 16); multiple cycles/year.
- Storage: Lyophilized at room temp; reconstituted refrigerated; do not freeze.
Dosing Protocol
- Initiation: 20 mg/day (100 units once in the morning).
- Titration: Increase by ~4 mg/wk.
- Target: 28–32 mg daily by Wk 4, split AM/PM.
- Frequency: Once daily (Wk 1); twice daily (Wk 2+) when volume >1.0 mL.
- Timing: Morning for single dose; morning + early evening for split dose.
- Break between cycles: After a cycle (8–16 weeks), a washout period of 4–8 weeks is recommended. Cerebrolysin has neurotrophic action—the break allows for assessment of results.
Washout & Cycle Restart
When can I restart?
After a cycle (8–16 weeks), a washout period of 4–8 weeks is recommended. Cerebrolysin has neurotrophic action—the break allows for assessment of results.
Minimum wait period: 4 weeks
Storage Instructions
- Lyophilized: Store at ≤25 °C in dry, dark conditions; refrigeration is acceptable.
- Reconstituted: Refrigerate at 2–8 °C; use within 7 days; do not freeze.
- Let stand at room temperature before injection; protect from light.
Important Notes
- Each injection ≤1.0 mL; split larger daily doses into two administrations.
- Log dose, time, and site.
Potential Benefits & Side Effects
Potential Benefits:
- Clinical trials report improvements in cognitive function in Alzheimer's disease and vascular dementia.
- Meta-analyses in acute ischemic stroke show improved neurological recovery.
- Generally well-tolerated; adverse events are comparable to placebo.
- Most common mild side effects: headache, dizziness, or agitation in a minority of patients.
- Subcutaneous administration may cause mild injection site reactions.
Potential Side Effects:
- Headache (5–15%).
- Dizziness (5–15%).
- Injection site reactions (pain, redness, swelling).
- Nausea or gastrointestinal discomfort.
- Insomnia or sleep disturbances.
- Fatigue or sweating.
- Rare (<1%): seizures, psychiatric symptoms, allergic reactions.
- Avoid high initial doses (≥80 mL).
⚠️ Serious Warnings & Long-Term Risks
The following warnings are based on published literature, FDA labels, and post-marketing surveillance. They do not constitute medical advice. Consult a healthcare professional.
Neurotrophic action — allergic reactions
As a peptide mixture from porcine brain, carries risk of allergic reactions. Rarely: dizziness, headache. Cochrane Review concluded 'insufficient evidence' for Alzheimer's.
📄 Cochrane Database Syst Rev 2015References
- International Peptide Society — Cerebrolysin Monograph: mechanism, pharmacology, clinical applications
View Source - Alzheimer's Drug Discovery Foundation — Cerebrolysin Cognitive Vitality Report
View Source - J Clinical Medicine (MDPI) — Cerebrolysin in Ischemic Stroke: A Systematic Review
View Source - PLOS One (2021) — Neuroprotective Effect of Cerebrolysin on Cerebral Ischemia (mice)
View Source - Cerebrolysin 24-Week RCT in Mild-to-Moderate Alzheimer's Disease — Cerebrolysin 24-week RCT in mild-to-moderate Alzheimer's disease
View Source
Recommended Supplements
Omega-3 DHA
Lion's Mane (Hericium erinaceus)
Phosphatidylserine
External Sources & Regulatory Status
Regulatory Approvals
Cerebrolysin® · Stroke / Dementia / TBI (1975)
Cerebrolysin® · Stroke / Dementia
Cerebrolysin® · Stroke / Dementia
Stroke / Dementia
Approved in 45+ countries (not FDA/EMA)
Educational information. Not medical advice, and no efficacy claim is implied. Regulatory approval is not a use recommendation by AllPeptides.eu.
Continue Your Research
Explore tools and guides related to this protocol.
Important Disclaimer
The content of this website is provided exclusively for informational and educational purposes within the context of research literature.
Read the full Disclaimer →